Biotechnology
Healthcare
Investing News
Market News
Technology
The Market Buzz
Moderna Announces mRNA-1345 Phase 3 Results
Moderna, Inc. (NASDAQ: MRNA) has announced positive data from its ConquerRSV Phase 3 trial of mRNA-1345, an investigational mRNA vaccine that targets respiratory syncytial virus in older adults. Following...